Detail akcie Arrowhead Phrmctcls online

Business Summary: Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Financial Summary: BRIEF: For the six months ended 31 March 2025, Arrowhead Pharmaceuticals Inc revenues increased from $3.6M to $545.2M. Net income totaled $197.4M vs. loss of $258.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest income increase of 90% to $17.2M (income), Stock-based compensation decrease of 25% to $15.8M (expense).